Biocon Stays Upbeat On Oral Insulin Plans
Executive Summary
India's largest biopharmaceutical company, Biocon, on May 17 sought to quell any confusion over its oral insulin program, underscoring that it stays confident of the molecule's prospects and is committed to taking it to the next stage of clinical development after the exit of partner Bristol-Myers Squibb (BMS).
You may also be interested in...
Novo Still Seeking Superior Tresiba Follow-On, Says CSO
Despite dropping its Phase II oral insulin program in the second half of 2016, Novo Nordisk's chief scientific officer says the company is quietly continuing to explore options for an oral therapy better than its leading insulin option, Tresiba.
PharmAsia News Business Bulletin
A new regular roundup of commercial stories appearing in Scrip's sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.
BMS option pact injects new life into Biocon's oral insulin
Biocon has entered into an agreement with Bristol-Myers Squibb, under which the US multinational holds an exclusive option to further develop and commercialize the Indian firm's prandial oral insulin candidate, IN-105, pending the outcome of certain clinical trials.